Please assess the completion status of the following clinical trial:

Trial Title: Effect and Safety Study of GP/FP Regimens in Advanced Nasopharyngeal Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven NPC diagnosis~* Elder than 18 years old are inclusive~* Recurrence or metastatic nasopharyngeal carcinoma with evidence of unsuitable for local treatment~* Amenable to regular follow-up~* Subjects with at least one measurable lesion (Tumor lesions that are situated in a previously irradiated area could not be considered measurable).~* Performance status: 0-1(ECOG)~* WBC \> 4.0X109/L, PLT \> 100X109/L, with normal hepatic function(AST, ALT \< 2.5 x upper limit of normal , and bilirubin \< 1.5 x upper limit of normal), with normal renal function (Creatinine \< 1.5 x upper limit of normal)~* No chemotherapy or radical radiotherapy received within 6 months prior to enrollment~* Life expectancy over twelve weeks~* Signed and dated informed consent before the start of specific protocol procedures~* Ability to comply with trial requirements.~Exclusion Criteria:~* Patient suitable for local treatment (eg. radiotherapy)~* Active clinically serious infections (\> grade 2 NCI-CTC version 3.0)~* Patient with central nervous system metastasis~* Patient life threatening medical condition~* Pregnant or breast-feeding patients. Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment. Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial and two weeks after the completion of trial.~* Performance status ≥ 2~* With a pre-existing peripheral neuropathy (National Cancer Institute Common Toxicity Criteria for Adverse Events \[NCI CTC\] grade ≥ 2)~* Serious concurrent illness~* Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors\[Ta, Tis \& T1\] or any cancer curatively treated \> 3 years prior to study entry.~* Patient refusing participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- gemcitabine and cisplatin (Type: EXPERIMENTAL): gemcitabine 1,000 mg/m2 over 30 to 60 minutes on days 1, 8, and plus cisplatin 80 mg/m2 on day 1, every 3 weeks.
- 5-Fluorouracil and cisplatin (Type: ACTIVE_COMPARATOR): 5-Fluorouracil 4,000 mg/m2 CIV over 96 hours and plus cisplatin 80 mg/m2 on day 1, every 3 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).